ECG score to predict ICD therapies in patients with nonischemic cardiomyopathy and primary prophylactic CRT-D

被引：1
作者：
Grett M. [1 ]
Christ M. [1 ]
Röing gen. Nölke J.-P. [1 ]
Trappe H.-J. [1 ]
机构：
[1] Medizinische Univ.-Klinik II (Kardiologie und Angiologie), Marien Hospital Herne, Ruhr Universität Bochum, Hölkeskampring 40, Herne
来源：
Herzschrittmachertherapie + Elektrophysiologie | 2017年 / 28卷 / 1期
关键词：
Cardiac resynchronization therapy; ECG score; Implantable cardioverter-defibrillator; Nonischemic cardiomyopathy; Risk stratification;
D O I：
10.1007/s00399-017-0490-6
中图分类号：
学科分类号：
摘要：
Background and problem: Recently published results of the DANISH study raise concerns, if primary prophylactic ICD implantations in patients with nonischemic cardiomyopathy (NICM) and severe reduced left ventricular ejection fraction (LVEF) should be performed without further risk stratification. There was no significant difference in the overall mortality of patients with or without ICD and CRT defibrillator (CRT-D) or CRT pacemaker (CRT-P), respectively. Clinical risk scores to identify patients with ischemic cardiomyopathy (ICM) who benefit most from an ICD have been recommended. The need for risk stratification systems concerning patients with NICM has been emphasized. Study design and methods: A retrospective study of 434 consecutive patients with CRT-D implantation was performed. Patients with no regular follow-up at our institution (n = 132), secondary prophylactic ICD indication (n = 61), and upgrade to CRT (n = 95) were excluded. The occurrence of an adequate ICD therapy was defined as the endpoint. Left ventricular ejection fraction (LVEF), genesis of the cardiomyopathy as well as the modified Selvester ECG score (MSES) for evaluation of the left ventricular scar burden were documented among other characteristics. Results: Within a median follow-up of 605 days, 24% of the patients experienced an adequate ICD therapy. These patients had significantly lower LVEF (20% vs. 23%), and the MSES was higher (7 vs. 3 points). There was no significant difference in patients suffering from ICM vs NICM. A receiver-operating-characteristic (ROC) analysis revealed a sensitivity of 0.914 and a specifity of 0.586 for MSES ≥4 to predict the occurrence of an ICD therapy. None of 35 patients suffering from NICM with MSES <4 experienced an ICD therapy. Interpretation: The evaluation of the left ventricular scar burden using MSES can be useful for the decision between CRT-D and CRT-P in patients suffering from NICM. © 2017, Springer Medizin Verlag GmbH.
引用
收藏
页码：48 / 53
页数：5
相关论文
共 15 条
[1]  
Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., Ip J.H., Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 20, pp. 225-237, (2005)
[2]  
Barsheshet A., Wang P.J., Moss A.J., Solomon S.D., Al-Ahmad A., McNitt S., Foster E., Huang D.T., Klein H.U., Zareba W., Eldar M., Goldenberg I., Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT, J Am Coll Cardiol, 57, 24, pp. 2416-2423, (2011)
[3]  
Barsheshet A., Moss A.J., Huang D.T., McNitt S., Zareba W., Goldenberg I., Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator, J Am Coll Cardiol, 59, 23, pp. 2075-2079, (2012)
[4]  
Disertori M., Quintarelli S., Mazzola S., Favalli V., Narula N., Arbustini E., The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy, Europace, 15, 12, pp. 1693-1701, (2013)
[5]  
Felker G.M., Shaw L.K., O'Connor C.M., A standardized definition of ischemic cardiomyopathy for use in clinical research, J Am Coll Cardiol, 39, 2, pp. 210-218, (2002)
[6]  
Fernandez-Armenta J., Berruezo A., Mont L., Sitges M., Andreu D., Silva E., Ortiz-Perez J.T., Tolosana J.M., de Caralt T.M., Perea R.J., Calvo N., Trucco E., Borras R., Matas M., Brugada J., Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy, Europace, 14, 11, pp. 1578-1586, (2012)
[7]  
Iles L., Pfluger H., Lefkovits L., Butler M.J., Kistler P.M., Kaye D.M., Taylor A.J., Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death, J Am Coll Cardiol, 57, 7, pp. 821-828, (2011)
[8]  
Kadish A., Dyer A., Daubert J.P., Quigg R., Estes N.A., Anderson K.P., Calkins H., Hoch D., Goldberger J., Shalaby A., Sanders W.E., Schaechter A., Levine J.H., Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N Engl J Med, 350, 21, pp. 2151-2158, (2004)
[9]  
Kirkfeldt R.E., Johansen J.B., Nohr E.A., Jorgensen O.D., Nielsen J.C., Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark, Eur Heart J, 35, 18, pp. 1186-1194, (2014)
[10]  
Kober L., Thune J.J., Nielsen J.C., Haarbo J., Videbaek L., Korup E., Jensen G., Hildebrandt P., Steffensen F.H., Bruun N.E., Eiskjaer H., Brandes A., Thogersen A.M., Gustafsson F., Egstrup K., Videbaek R., Hassager C., Svendsen J.H., Hofsten D.E., Torp-Pedersen C., Pehrson S., Defibrillator implantation in patients with nonischemic systolic heart failure, N Engl J Med, 375, 13, pp. 1221-1230, (2016)
12